Brief Article
Copyright ©2012 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Nov 18, 2012; 4(11): 443-449
Published online Nov 18, 2012. doi: 10.4329/wjr.v4.i11.443
Novel eradicative high-dose rate brachytherapy for internal mammary lymph node metastasis from breast cancer
Kazushi Kishi, Hirokazu Tanino, Tetsuo Sonomura, Shintaro Shirai, Yasutaka Noda, Morio Sato, Yoshitaka Okamura
Kazushi Kishi, Department of Radiation Oncology, Wakayama Medical University, Wakayama 641-8510, Japan
Hirokazu Tanino, Department of Surgery, Naga Hospital, Uchida 1282, Kinokawa City, Wakayama Prefecture 649-6414, Japan
Tetsuo Sonomura, Shintaro Shirai, Yasutaka Noda, Morio Sato, Department of Radiology, Wakayama Medical University, Wakayama 641-8510, Japan
Yoshitaka Okamura, 1st Department of Surgery, Wakayama Medical University, Wakayama 641-8510, Japan
Author contributions: Kishi K developed the methods, treated the patients and wrote the manuscript; Tanino H managed and treated the patients; Sonomura T, Shirai S, and Noda Y supported this clinical work; Sato M and Okamura Y approved the manuscript.
Supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT), grant number 23659595 (in part)
Correspondence to: Kazushi Kishi, MD, PhD, Department of Radiation Oncology, Wakayama Medical University, Wakayama 641-8510, Japan. kazushi.kishi@gmail.com
Telephone: +81-73-441-0605 Fax: +81-73-441-0605
Received: June 11, 2012
Revised: September 18, 2012
Accepted: September 26, 2012
Published online: November 18, 2012
Abstract

AIM: To develop a method of delivering an eradicative high radiotherapeutic dose safely preserving the surrounding skin in the treatment of internal mammary lymph node metastasis (IMLNM) of breast cancer.

METHODS: We report a 38-year-old female patient with a solo IMLNM showing no response to 60 Gy in 2.5 Gy fractions of external beam radiotherapy. To eradicate this tumor, a boost brachytherapy plan was created after percutaneous insertion of an applicator needle into the IMLNM lesion avoiding the pleura and vessels under ultrasound monitoring. According to the dose distribution, the required thickness of a spacer between the skin and the tumor was determined, and hyaluronic gel was injected up to this thickness under ultrasound monitoring. We evaluated skin doses, target doses and clinical outcome.

RESULTS: All procedures were performed easily. Sixteen Gy (34.7 Gy equivalent in 2 Gy fractions calculated by the linear quadratic model at α/β = 10: EQD2, α/β = 10, cumulative total was 101.9 Gy EQD10) to 100% of the target volume was irradiated with cumulative maximum skin dose of 70 Gy EQD2, α/β = 3 which was 98.7 Gy EQD2, α/β = 3 without spacer. No procedure related- or late complications and no local recurrence at the treated site were observed for three years until expiration.

CONCLUSION: We consider that this procedure will provide an eradicative high-dose irradiation to IMLNM of breast cancer, preserving skin from overdose complications.

Keywords: Brachytherapy; Hyaluronate; Internal mammary lymph node; Metastasis; Skin preservation; Breast cancer; Organ at risk